Browse > Article
http://dx.doi.org/10.3904/kjm.2014.87.2.240

Atypical Femoral Fracture in a Patient with Rheumatoid Arthritis  

Kim, Dam (Department of Rheumatology, Hospital for Rheumatic Diseases, Hanyang University College of Medicine)
Jung, Sodam (Department of Internal Medicine, Hanyang University College of Medicine)
Son, Chang-Nam (Department of Rheumatology, Hospital for Rheumatic Diseases, Hanyang University College of Medicine)
Choi, Ji-Young (Department of Rheumatology, Hospital for Rheumatic Diseases, Hanyang University College of Medicine)
Lee, Seunghun (Department of Radiology, Hanyang University College of Medicine)
Kim, Yee-Suk (Department of Orthoperdic Surgery, Hanyang University College of Medicine)
Sung, Yoon-Kyoung (Department of Rheumatology, Hospital for Rheumatic Diseases, Hanyang University College of Medicine)
Publication Information
The Korean Journal of Medicine / v.87, no.2, 2014 , pp. 240-244 More about this Journal
Abstract
Atypical femoral fractures are characterized by a subtrochanteric or diaphyseal location. Recent studies have suggested that long-term treatment with bisphosphonates might be associated with the occurrence of atypical femoral fractures. The present report describes a case involving a 60-year-old woman with left buttock pain that was unassociated with trauma. Her hip pain was initially considered to be a symptom of her underlying rheumatoid arthritis, but a plain radiography, bone scintigraphy, and magnetic resonance imaging revealed an insufficiency fracture in the lateral shaft of the left proximal femur. She had been treated with a bisphosphonate for 4.5 years because of a previous vertebral fracture. Her chronic, long-term rheumatoid arthritis and history of bisphosphonate administration were considered to be associated with the development of her atypical femoral fracture.
Keywords
Femoral fracture; Arthritis, Rheumatoid; Alendronate;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346-350.   DOI   ScienceOn
2 Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a longterm complication of alendronate therapy? Injury 2008;39:224-231.   DOI   ScienceOn
3 Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA 2009;302:1573-1579.   DOI   ScienceOn
4 Edwards BJ, Bunta AD, Lane J, et al. Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am 2013;95:297-307.   DOI   ScienceOn
5 Lee YK, Ha YC, Park C, Yoo JJ, Shin CS, Koo KH. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int 2013;24:707-711.   DOI   ScienceOn
6 Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-1737.   DOI   ScienceOn
7 Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013;28:1729-1737.   DOI
8 Sung YB, Choi JY, Um KS. Bisphosphonate related atypical femoral fracture. Hip Pelvis 2013;25:66-71.   DOI
9 Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br 2010;92:679-686.
10 Girgis CM, Sher D, Seibel MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010;362:1848-1849.   DOI   ScienceOn